Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab-CHOP with Pegylated Liposomal Doxorubicin in older patients with B-cell NHL
NCT00101010Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2005
- Primary completion
- Sep 2014
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
A Phase 2 trial of pegylated liposomal doxorubicin in diffuse large B-cell lymphoma (DLBCL), sponsored by University of Texas MD Anderson Cancer Center. Started Sep 2005; status: completed.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT00101010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00101010.